Pharsight

1. Levitra patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP10183693A	2017-07-12	Accord Healthcare Ltd	Opposition rejected
EP10183693A	2017-07-12	Teva Pharmaceutical Industries Ltd	Opposition rejected
EP10183693A	2017-07-11	Zentiva k.s.	Opposition rejected
EP03763695A	2012-09-28	Accord Healthcare Ltd	Revoked
EP03763695A	2012-09-27	Zentiva k.s.	Revoked

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7696206	BAYER HLTHCARE	2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors	Oct, 2018 (5 years ago)
US6362178	BAYER HLTHCARE	2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors	Oct, 2018 (5 years ago)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8841446	BAYER HLTHCARE	Medicaments containing vardenafil hydrochloride trihydrate	Jul, 2023 (9 months ago)
US8273876	BAYER HLTHCARE	Medicaments containing vardenafil hydrochloride trihydrate	Jul, 2027 (3 years from now)

Market Authorisation Date: 19 August, 2003

Treatment: Treatment of erectile dysfunction by administering a film-coated tablet; Erectile dysfunction

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
2.5 mg	04 Sep, 2009	1	03 May, 2012	31 Oct, 2018	Deferred
5 mg and 10 mg	10 Jul, 2009	1	03 May, 2012	31 Oct, 2018	Deferred
20 mg	05 Mar, 2009	1	03 May, 2012	31 Oct, 2018	Deferred

Strength	Dosage	Availability
EQ 2.5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET;ORAL	Discontinued
EQ 5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET;ORAL	Discontinued
EQ 20MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET;ORAL	Discontinued
EQ 10MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET;ORAL	Discontinued

Application	Filing Date	Opposition Party	Legal Status

EP06706994A	2013-01-11	Accord Healthcare Ltd	Opposition rejected
EP06706994A	2013-01-11	Generics [UK] Limited	Opposition rejected

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7696206	BAYER HLTHCARE	2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors	Oct, 2018 (5 years ago)
US6362178	BAYER HLTHCARE	2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors	Oct, 2018 (5 years ago)
US8613950	BAYER HLTHCARE	Pharmaceutical forms with improved pharmacokinetic properties	Dec, 2028 (4 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Dosage Form(NDF)	Jun 17, 2013

Market Authorisation Date: 17 June, 2010

Treatment: Treatment of erectile dysfunction

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL